Abstracts tagged "SLE"

Abstract Number: 2638 • 2017 ACR/ARHP Annual Meeting
Inducible cAMP Early Repressor Promotes Glycolysis By Inhibiting the Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 2 in Th17 Cells
Michihito Kono, Nobuya Yoshida, Nicole E. Skinner and George C. Tsokos, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Th17 cells are key players in SLE. Because Th17 cells use mainly glycolysis, blocking glycolysis can inhibit Th17 cell differentiation and treatment of lupus-prone…
Abstract Number: 930 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Modified-Release Prednisone in Managing Moderate Activity SLE during Pregnancy: An Implemented Case-Control Study
Marianna Meroni¹, Véronique Laure Ramoni², Massimiliano Parodi³, Paolo Stobbione³ and Maurizio Cutolo⁴, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, ²Division of Rheumatology, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ³Rheumatology Unit, Internal Medicine Department, A.O. S.S. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy, Alessandria, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) can affect young women and pregnancy still represents a challenge. Prednisone is safely used, at low doses (<7.5 mg daily),…
Abstract Number: 1655 • 2017 ACR/ARHP Annual Meeting
Interferon b Blockade Rescues Human BM-MSC Osteoblastogenesis Defects in Systemic Lupus Erythematosus
Lin Gao¹, Jennifer H. Anolik² and R. John Looney³, ¹medicine- allergy, immunology and rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bone marrow mesenchymal stromal cells (BM-MSCs) are multipotent stem cells that can differentiate into chondrocytes, osteoblasts and adipocytes. SLE has been implicated as a…
Abstract Number: 2563 • 2017 ACR/ARHP Annual Meeting
SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice
Akiko Nagasu¹, Tomoyuki Mukai¹, Masanori Iseki², Hajime Nagasu³, Shunichi Fujita¹, Takafumi Mito¹, Shoko Kodama¹, Yumi Sasae⁴, Naoki Kashihara³, Katsuhiko Ishihara², Yasuyoshi Ueki⁵ and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ³Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Rheumatology, Kawasaki Medical School, Kurashiki Okayama, Japan, ⁵Department of Oral and Craniofacial Sciences, School of Dentistry, University of Missouri-Kansas City, Missouri-Kansas City, MO
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, leading to multiple organ dysfunction. SH3BP2 (Src homology domain 3…
Abstract Number: 2645 • 2017 ACR/ARHP Annual Meeting
The Internalization of DNA-Antibodies By Podocytes during Lupus Nephritis
Anja Römer-Hillmann¹, Elisabeth Jung², Annika Engbers¹, Marcel Reinhardt¹, Hedda Wardemann³, Thomas Pap⁴ and Annett Jacobi⁵, ¹Institute of Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, ²Department of Internal Medicine D, Rheumatology, University Hospital Muenster, Muenster, Germany, ³Deutsches Krebsforschungszentrum, Heidelberg, Germany, ⁴Institute for Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, ⁵Internal Medicine, Ruppiner Kliniken GmbH, Neuruppin, Germany
Background/Purpose: Podocytes are postmitotic visceral epithelial cells, located at the Bowmans capsule of the kidney building up the slit diaphragm with their foot processes to…
Abstract Number: 177 • 2017 ACR/ARHP Annual Meeting
Intronic Variants of the B-Cell Proliferator RASGRP3 Affect Its Expression, and Might Contribute to Lupus Risk
Bhupinder Singh¹, Philip Borden², Julio Molineros³, Celi Sun³, Loren Looger² and Swapan Nath¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, OKlahoma City, OK, ²Howard Hughes Medical Institute, Ashburn, VA, ³Oklahoma Medical Research Foundation, OKlahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease with complex genetic underpinnings. Variants from RASGRP3 (RAS Guanyl Releasing Protein 3) is one of…
Abstract Number: 986 • 2017 ACR/ARHP Annual Meeting
Do Death Certificates Underestimate the Burden of Rare Diseases: The Example of Systemic Lupus Erythematosus Mortality in Sweden
Titilola Falasinnu¹, Marios Rossides², Yashaar Chaichian³ and Julia F Simard⁴, ¹Health Research and Policy, Stanford University, Stanford, CA, ²Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Medicine, Immunology & Rheumatology Division, Stanford School of Medicine, Stanford, CA, ⁴Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA
Background/Purpose: Routine data sources such as death certificates are used to estimate the burden or cost of disease in a population. However, mortality due to…
Abstract Number: 1658 • 2017 ACR/ARHP Annual Meeting
Interferon Related Soluble Mediator Concentrations Significantly Correlate with Disease Activity in SLE Patients with Active Interferon Pathways
Rufei Lu¹, Cristina Arriens², Teresa Aberle³, Stan Kamp³, Melissa E. Munroe³, Tim Gross¹, Wade DeJager³, Susan Macwana³, Virginia C. Roberts³, Stephen Apel⁴, Hua Chen³, Eliza Chakravarty⁵, Katherine Thanou³, Joan T. Merrill⁶ and Judith A. James⁷, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical research af, Edmond, OK, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose : Interferon (IFN) pathways are dysregulated in a subset of patients with systemic lupus erythematosus (SLE). IFN dysregulation likely contributes to SLE pathogenesis and…
Abstract Number: 2568 • 2017 ACR/ARHP Annual Meeting
Prophylactic and Therapeutic Administration of a JAK1-Selective Inhibitor Blocks and Reverses Nephritis and Sialadenitis in NZB/W-F1 Mice
Rachel Twomey¹, Stuart Perper¹, Susan Westmoreland¹, Terry Melim¹, Soumya Mitra¹, Zheng Liu¹, Manuel Duval¹, Carolyn Cuff², Andrew Long¹, Anthony Slavin² and Stephen Clarke¹, ¹AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²Immunology Discovery, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Signaling of most cytokine receptors occurs through the JAK-STAT pathway. This is true of cytokines linked to the etiology of systemic lupus erythematosus (SLE)…
Abstract Number: 2646 • 2017 ACR/ARHP Annual Meeting
Premature Senescence of Naive CD4+ T-Cells in Systemic Lupus Erythematosus
Patrizia Fasching¹, Johannes Fessler², Andrea Raicht³, Angelika Lackner², Rusmir Husic¹, Winfried Graninger², Wolfgang Schwinger³, Martin Stradner¹ and Christian Dejaco¹, ¹Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ²Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³Division of Pediatric Hemato-Oncology, Medical University of Graz, Graz, Austria
Background/Purpose: The pool of naïve CD4+ T-cells is reduced in patients suffering from systemic lupus erythematosus (SLE). We aimed to study if the occurrence of…
Abstract Number: 181 • 2017 ACR/ARHP Annual Meeting
Identification of Disease-Susceptible Lncrna Contributed to Abnormal Activation of Type I Interferon Pathway in Systemic Lupus Erythematosus
Nan Shen^1,2, Yuanjia Tang³, Zhixin Xue³ and Chaojie Cui⁴, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ²The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH, ³Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ⁴Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Dysregulation or dysfunction of some key moleculars in signaling pathway is involved in disease pathogenesis. Long non-coding RNA (lncRNA), as a regulator of gene…
Abstract Number: 987 • 2017 ACR/ARHP Annual Meeting
Death Certificates Do Not Accurately Identify SLE Patients
Kelly Kaysen, Cristina Drenkard, Gaobin Bao and S. Sam Lim, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Mortality rates are higher in SLE patients compared to the general population, and research on SLE mortality is ongoing. The majority of mortality studies…
Abstract Number: 1660 • 2017 ACR/ARHP Annual Meeting
Prolactin Induces an Interferon Signature in Monocytes and Drives IRF1-HAT Interactions
Yiu Tak Leung¹, Lihua Shi², Kelly Maurer², Li Song³ and Kathleen E. Sullivan⁴, ¹Temple University, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Allergy Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Epigenetic changes in systemic lupus erythematosus (SLE) offer a potential explanation for the chronicity of disease. We previously found that interferon regulatory factor-1(IRF1) binding…
Abstract Number: 2569 • 2017 ACR/ARHP Annual Meeting
Serine/Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Regulator of T Cell Function and Its Selective Deficiency in T Lymphocytes Leads to Autoimmunity and Lupus-like Nephritis
Vaishali R. Moulton¹, Takayuki Katsuyama¹, Hao Li¹, Michael W. Mosho¹, Andrew R. Gillooly² and George C. Tsokos¹, ¹Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/ Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) exhibit defects in signaling including a reduced expression of the CD3 zeta signaling chain, and…
Abstract Number: 2652 • 2017 ACR/ARHP Annual Meeting
Abnormal Expression of Long Noncoding RNA Lncrna-CMPK2 Facilitates Neutrophils Interferon Production By TLR7/8 Agonist Stimulation in SLE
Zhixin Xue, Yuanjia Tang and Nan Shen, Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Interferon plays prominent role in systemic lupus erythematosus (SLE) pathogenesis while the source of high interferon in SLE is still confused, several cell types…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].